KEVIN MAYS: Open Payments
NPI 1598735144 · LEAWOOD, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$79,465 in 264 payments from 19 companies in 2025. Trend: 2023 $120,225 · 2024 $87,275 · 2025 $79,465
Speaker / faculty: $36,255Honoraria: $22,800Consulting: $10,408Travel & lodging: $5,228Food & beverage: $4,771Education: $4
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 50 | $26,568 |
| Neurocrine BioSciences, Inc. | 31 | $24,135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 46 | $21,960 |
| ABBVIE INC. | 31 | $4,907 |
| Vanda Pharmaceuticals Inc. | 17 | $425 |
| Otsuka America Pharmaceutical, Inc. | 23 | $400 |
| E.R. Squibb & Sons, L.L.C. | 16 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $168 |
| Collegium Pharmaceutical, Inc. | 15 | $154 |
| Almatica Pharma LLC | 5 | $99 |
Products named: Qelbree, INGREZZA, CAPLYTA, VRAYLAR, HETLIOZ, REXULTI, COBENFY, ABILIFY ASIMTUFII.
Industry payments across KS — which companies pay providers there.
